News
MDWD
14.45
-1.57%
-0.23
Weekly Report: what happened at MDWD last week (0219-0223)?
Weekly Report · 2d ago
Weekly Report: what happened at MDWD last week (0212-0216)?
Weekly Report · 02/19 12:27
Mediwound’s EscharEx: A Buy Rating on Potential Market Disruption and Superior Clinical Performance
TipRanks · 02/14 12:45
Analysts Are Bullish on Top Healthcare Stocks: Immunovant (IMVT), 4D Molecular Therapeutics (FDMT)
TipRanks · 02/13 11:20
Health Care Sector Update for 02/12/2024: ANTX, MDWD, GILD, CBAY, TTOO
NASDAQ · 02/12 20:59
MediWound stock climbs 9% on Phase 2 data for wound care treatment
MediWound stock climbs 9% on Phase 2 data for wound care treatment EscharEx. The Israeli company reported positive data for its chronic wound treatment. A Phase 3 study of the treatment is expected to begin in the second half of 2024. Mediwound shares climbed 9% Monday.
Seeking Alpha · 02/12 17:19
MediWound Reports Positive Results In Head-to-head Comparison Of EscharEx Vs SANTYL
NASDAQ · 02/12 13:21
Weekly Report: what happened at MDWD last week (0205-0209)?
Weekly Report · 02/12 12:12
MediWound Announced The Results Of Head-To-Head Comparison Analyses Of EscharEx To Collagenase SANTYL Ointment, Approved By The FDA For Debriding Chronic Dermal Ulcers
Results from the previously disclosed Phase II study demonstrated superiority of EscharEx over a gel vehicle. The study evaluated the safety and efficacy of escharEx in the treatment of non-viable tissue. The secondary analyses assessed the incidence and time to complete debridement and wound closure.
Benzinga · 02/12 12:04
Weekly Report: what happened at MDWD last week (0129-0202)?
Weekly Report · 02/05 12:25
Weekly Report: what happened at MDWD last week (0122-0126)?
Weekly Report · 01/29 12:08
Weekly Report: what happened at MDWD last week (0115-0119)?
Weekly Report · 01/22 12:14
HC Wainwright & Co. Maintains Buy on MediWound, Raises Price Target to $28
Benzinga · 01/16 12:27
Weekly Report: what happened at MDWD last week (0108-0112)?
Weekly Report · 01/15 12:08
Mediwound Poised for Growth: Buy Rating Affirmed Amidst FDA Progress, Revenue Forecasts, and Expansion Potential
TipRanks · 01/12 18:35
FDA accepts MediWound application for NexoBrid pediatric approval
Healthcare FDA accepts MediWound application for NexoBrid pediatric approval. The product is currently approved in the US for use on adults. Israeli biotech Mediwound said the FDA has accepted its supplemental Biologics License Application to have its wound care product approved for treatment of burns in pediatric patients.
Seeking Alpha · 01/09 16:44
More
Webull provides a variety of real-time MDWD stock news. You can receive the latest news about Mediwound through multiple platforms. This information may help you make smarter investment decisions.
About MDWD
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.